<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Mestranol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01357</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination <span class="caps">ORAL</span> contraceptives. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01357/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01357/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01357.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01357.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01357.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01357.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01357.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01357">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>72-33-3</td></tr><tr><th>Weight</th><td>Average: 310.4299<br>Monoisotopic: 310.193280076</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>26</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>IMSSROKUHAOUJS-ZTUUXWJNNA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/s2</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1S,10R,11S,14R,15S)-14-ethynyl-5-methoxy-15-methyltetracyclo[8.7.0.0&#178;,&#8311;.0&#185;&#185;,&#185;&#8309;]heptadeca-2(7),3,5-trien-14-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC)C=C3</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB01357.gif?1265922770">show</a>(9.65 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Hydroxysteroids</td></tr><tr><th>Direct parent</th><td>Hydroxysteroids</td></tr><tr><th>Alternative parents</th><td>Phenanthrenes and Derivatives; Tetralins; Anisoles; Alkyl Aryl Ethers; Ynones; Tertiary Alcohols; Cyclic Alcohols and Derivatives; Polyamines</td></tr><tr><th>Substituents</th><td>phenanthrene; tetralin; anisole; phenol ether; alkyl aryl ether; benzene; ynone; tertiary alcohol; cyclic alcohol; ether; polyamine; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the hydroxysteroids. These are compounds containing an steroid backbone, with at least one hydrogen substituted by an hydroxyl group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Mestranol was used as one of the first oral contraceptives.</td></tr><tr><th>Pharmacodynamics</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Mechanism of action</th><td>Mestranol is the 3-methyl ether of ethinylestradiol. Ethinylestradiol, is a synthetic derivative of estradiol. Ethinylestradiol is orally bio-active and the estrogen used in almost all modern formulations of combined oral contraceptive pills.  It binds to (and activates) the estrogen receptor. Mestranol is a biologically inactive prodrug of ethinylestradiol to which it is demethylated in the liver with a conversion efficiency of 70%.

Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Mestranol</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00457">17&#946;-ethinylestradiol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/466">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9929</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9465</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8463</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.656</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6099</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8382</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8148</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7521</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7656</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9334</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.7721</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.5232</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7758</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8714
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9829
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.5234 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8958
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.5679
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>The contraceptive increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB01060">Amoxicillin</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00415">Ampicillin</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Ritonavir could decrease the contraceptive efficacy</td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>Aprepitant could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Artemether may decrease the effectiveness of mestranol by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy. </td></tr><tr><td><a href="/drugs/DB01053">Benzylpenicillin</a></td><td>This anti-infectious agent could decreases the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00559">Bosentan</a></td><td>Decreases the effect of contraceptive</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00578">Carbenicillin</a></td><td>This anti-infectious agent could decreases the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00766">Clavulanate</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB01147">Cloxacillin</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens). Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. Ethinyl estradiol patches and vaginal rings may also be somewhat impacted by this interaction, though the extent and significance of such an interaction is uncertain.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>The contraceptive increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB00618">Demeclocycline</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00485">Dicloxacillin</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00301">Flucloxacillin</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00400">Griseofulvin</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00555">Lamotrigine</a></td><td>The oral contraceptive decreases the effect of lamotrigine</td></tr><tr><td><a href="/drugs/DB01017">Minocycline</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00745">Modafinil</a></td><td>Modafinil decreases the effect of the contraceptive</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Ritonavir could decrease the contraceptive efficacy</td></tr><tr><td><a href="/drugs/DB00776">Oxcarbazepine</a></td><td>Oxcarbazepine decreases the effect of the contraceptive</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>The contraceptive increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB00417">Penicillin V</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB01132">Pioglitazone</a></td><td>Possible loss of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00319">Piperacillin</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB01604">Pivampicillin</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The estrogenic agent, mestranol, may increase the effect of the corticosteroid, prednisolone.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The estrogenic agent, mestranol, may increase the effect of corticosteroid, prednisone.</td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00481">Raloxifene</a></td><td>Association not recommended</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>This product may cause a slight decrease of the contraceptive effect</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00759">Tetracycline</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>The contraceptive increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB00599">Thiopental</a></td><td>Thiopental may decrease the effect of Mestranol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Mestranol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Mestranol. Use an alternate form of contraception or monitor for estrogen deficiency if Mestranol is used for hormone replacement therapy. </td></tr><tr><td><a href="/drugs/DB00697">Tizanidine</a></td><td>Oral contraceptives decrease the clearance of Tizanidine.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Mestranol. Consider alternate therapy or monitor for changes in Mestranol therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00273">Topiramate</a></td><td>Topiramate may decrease the effect of the oral contraceptive, Mestranol. An alternate form of contraception should be used during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>Oral Tretinoin may decrease the effect of oral contraceptive, Mestranol. An alternate form of contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Mestranol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if mestranol is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>